<i>HER2</i>-Positive Breast Cancer Patients with Pre-Treatment Axillary Involvement or Postmenopausal Status Benefit from Neoadjuvant Rather than Adjuvant Chemotherapy Plus Trastuzumab Regimens

<i>HER2</i>-Positive Breast Cancer Patients with Pre-Treatment Axillary Involvement or Postmenopausal Status Benefit from Neoadjuvant Rather than Adjuvant Chemotherapy Plus Trastuzumab Regimens

Background: No survival benefit has yet been demonstrated for neoadjuvant chemotherapy (NAC) against <i>HER2</i>-positive tumors in patients with early breast cancer (BC). The objective of this study was to compare the prognosis of <i>HER2</i>-positive BC patients treated wit...

Full description

Bibliographic Details
Main Authors: Enora Laas, Arnaud Bresset, Jean-Guillaume Féron, Claire Le Gal, Lauren Darrigues, Florence Coussy, Beatriz Grandal, Lucie Laot, Jean-Yves Pierga, Fabien Reyal, Anne-Sophie Hamy
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:Cancers
Subjects:
breast cancer
neoadjuvant chemotherapy
adjuvant chemotherapy
<i>HER2</i>-positive tumors
Online Access:https://www.mdpi.com/2072-6694/13/3/370

Similar Items

Similar Items